Gefitinib in Treating Patients With Malignant Mesothelioma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of gefitinib in treating patients who have
malignant mesothelioma. Biological therapies such as gefitinib may interfere with the growth
of the tumor cells and slow the growth of malignant mesothelioma